Tango Pharma - רווח נקי למניה בארבעת הרבעונים האחרונים TNGX

Tango Therapeutics focuses on precision cancer therapy through synthetic lethality by developing targeted molecules. The company is currently scaling its innovative portfolio and validating drug candidates. The business is shielded from macroeconomic shocks and is not subject to seasonality. The annual net income per share growth rate (ttm) clearly illustrates the capital dynamics, where the -49.30 mark serves as a real-time assessment of current efficiency.
TNGX (Tango Therapeutics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Assessing the financial stability of Tango Therapeutics (TNGX) requires an analysis of the business's ability to convert research and development into actual revenue. The current YoY ttm net income per share growth, standing at -49.30, measures the annual change in profit over 12 months, which is critical for a biotech company at the commercialization stage of targeted oncology drugs for genetic deletions.